Bruce R. Rowley

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

Scott M. Wilhelm, Christopher Carter, LiYa Tang et al. · Cancer Research · 2004 · 4K citations · Full text

Mutant Braf, Raf/mek/erk Pathway, Medicine +12

Syk tyrosine kinase required for mouse viability and B-cell development

Alec M. Cheng, Bruce R. Rowley, William Pao et al. · Nature · 1995 · 625 citations

Knockout Mouse, Developmental Biology, Signal Transduction +11

BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models

Ningshu Liu, Bruce R. Rowley, Cathy Bull et al. · Molecular Cancer Therapeutics · 2013 · 251 citations

Molecular Pharmacology, Tumor Biology, Pi3k Inhibitors +15

Tumor Development by Transgenic Expression of a Constitutively Active Insulin-Like Growth Factor I Receptor

Joan M. Carboni, Adrian V. Lee, Darryl L. Hadsell et al. · Cancer Research · 2005 · 203 citations · Full text

Receptor Antagonists, Cell Proliferation, Tumor Biology +16

Murine pregnancy decidua produces a unique immunosuppressive molecule related to transforming growth factor <i>beta</i>-2.

David A. Clark, K C Flanders, Daljeet Banwatt et al. · The Journal of Immunology · 1990 · 154 citations · Full text